Theracryf（TCF）株式概要Theracryf Plcは臨床段階の治療薬企業で、腫瘍学と行動脳障害の治療薬開発に従事している。 詳細TCF ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間2.8%増加しました。 リスク分析意味のある時価総額がありません ( £5M )今後3年間の収益は年平均13.2%減少すると予測されている。 収益が 100 万ドル未満 ( £0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るTCF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.0023該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m838k2016201920222025202620282031Revenue UK£1.1Earnings UK£0.2AdvancedSet Fair ValueView all narrativesTheracryf Plc 競合他社CardiogeniSymbol: OFEX:CGNIMarket cap: UK£6.7mOptiBiotix HealthSymbol: AIM:OPTIMarket cap: UK£5.9mSolvonis TherapeuticsSymbol: LSE:SVNSMarket cap: UK£16.7mAptamer GroupSymbol: AIM:APTAMarket cap: UK£19.9m価格と性能株価の高値、安値、推移の概要Theracryf過去の株価現在の株価UK£0.002352週高値UK£0.00352週安値UK£0.0018ベータ1.41ヶ月の変化-8.00%3ヶ月変化2.22%1年変化-6.12%3年間の変化-94.10%5年間の変化-97.23%IPOからの変化-99.35%最新ニュースNew Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (UK£5.26m market cap, or US$7.06m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change).お知らせ • Jan 27Theracryf plc Receives Notice of Allowance from the Canadian Patent Office for Its Orexin-1 Addiction ProgrammeTheraCryf plc announced that it has received a Notice of Allowance from the Canadian Patent Office for its Orexin-1 (Ox-1) addiction programme, alongside a positive update on ongoing preclinical development. The Canadian patent represents the final major market to grant for this intellectual property, completing broad protection across the US, Europe, Canada and key Asian territories. The patent provides Composition of Matter, the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme. The Group also reports continued progress on its Maximum Tolerated Dose (MTD) and Dose Range Finding (DRF) studies, which commenced earlier this month. The MTD have now been successfully completed, with two species dosed up to the regulatory maximum, 1g/kg of the orexin-1 blocker, with no adverse clinical observations reported. This favourable outcome further de-risks the programme and enables progression into repeat-dose DRF studies, the results of which will inform the dosing for the planned 28-day regulatory toxicity studies scheduled in First Quarter and Second Quarter 2026, depending on species. This is a near final step on the path to IND/CTA readiness targeted for 2026. TheraCryf's lead programme, is a novel, best-in-class orexin-1 blocker., being developed as a potential treatment for addiction, including alcohol and other substance use disorders. The programme demonstrates class-leading selectivity and high receptor occupancy, characteristics which are expected to translate into improved tolerability and efficacy. Blocking the orexin-1 pathway has been shown to reduce aberrant substance-seeking behaviour in animal models, and the orexin pathway has attracted strong interest in the pharmaceutical sector. Addiction represents a large and growing global market, with substantial unmet medical need and significant human, social and economic impact, making it an attractive indication for development and commercialisation.お知らせ • Jan 05Theracryf Plc Starts 2026 Positive, A Key Milestone on the Path to Clinical Ready for Its Ox-1 Orexin Bladder Potential Treatment for Addiction DisordersTheraCryf plc has started 2026 positively, achieving a key milestone on the path to clinical readiness for its Ox-1 orexin blocker potential treatment for addictive disorders. Process for large-scale manufacturing of drug substance established Scale-up achieved on schedule with a manufacturing yield in excess of target 10.6kg produced to supply critical 28-day regulatory toxicology studies. Dosing in two species has now commenced to identify maximum tolerated dose for 28-day regulatory toxicology study. These studies will begin in first quarter of 2026, depending on species. All studies on schedule to complete third quarter of 2026. Manufacturing scale-up and completion of 28-day toxicology studies were highlighted, during the successful placing in March 2025, as the two key milestones remaining in the Ox-1 programme to achieve clinical readiness. Scale-up of the Ox-1 compound to 10kg has now been achieved on schedule and with a yield in excess of expectations. This drug substance will be used in the 28-day regulatory toxicology projects scheduled to commence, in first quarter and second quarter of 2020 in two species. These studies will provide essential data for the planned regulatory submission later in the year and represent the last major hurdle to achieving that goal. Before starting the 28-day toxicology studies, the Maximum Tolerated Dose and Dose Range Finding studies need to be completed. This work has now started. These studies will identify the 'therapeutic index' of the orexin-1 blocker - that is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Ox-1 is TheraCryf's lead asset, an orexin-1 blocker, being developed as a potential treatment for addiction, blocks a pathway in the brain (orexin-1) known to be over-active in individuals with addiction. This group of conditions have significant human and economic impact globally. Blocking the overactivity of this pathway is known to reduce aberrant substance seeking behaviour in animal models. Drugs that can block this pathway have generated significant commercial interest and TheraCryf's orexin-1 blocker is the most selective yet developed, indicating class leading potential.お知らせ • Nov 24Theracryf Plc to Report First Half, 2026 Results on Dec 03, 2025Theracryf Plc announced that they will report first half, 2026 results on Dec 03, 2025お知らせ • Nov 05TheraCryf plc Provides an Update on Key Activity in its Ox-1 Development ProgrammeTheraCryf plc provided an update on key activity in its Ox-1 development programme. 0.5kg scale-up completed, ahead of schedule; Manufacturing of 2kg human grade material initiated; 10kg manufacturing scale-up proceeding to plan. Successful achievement of compound scale-up, from small gram quantities to 0.5kg, is a significant milestone for the Company. This milestone was reached ahead of schedule and with no issues. After formulation to the optimal dosage form, the compound will be used in an in vivo study to identify the 'therapeutic index' this is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Data from this study will inform dosing in the key 28-day toxicology studies scheduled to commence in early 2026. The 28-day toxicology studies will be supplied by the 10kg compound scale-up which is currently proceeding to plan and schedule. The Company have also now initiated work through its partner, Pharmaron, to manufacture drug product for human use in the Ph1 healthy volunteer study. This process is conducted under special conditions, referred to as GMP (Good Manufacturing Practice), a regulatory standard to ensure safety and quality in order that the product can be given to people. Data from this activity will form part of the regulatory package required for the clinical trial application.New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.47m market cap, or US$5.95m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change).最新情報をもっと見るRecent updatesNew Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (UK£5.26m market cap, or US$7.06m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change).お知らせ • Jan 27Theracryf plc Receives Notice of Allowance from the Canadian Patent Office for Its Orexin-1 Addiction ProgrammeTheraCryf plc announced that it has received a Notice of Allowance from the Canadian Patent Office for its Orexin-1 (Ox-1) addiction programme, alongside a positive update on ongoing preclinical development. The Canadian patent represents the final major market to grant for this intellectual property, completing broad protection across the US, Europe, Canada and key Asian territories. The patent provides Composition of Matter, the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme. The Group also reports continued progress on its Maximum Tolerated Dose (MTD) and Dose Range Finding (DRF) studies, which commenced earlier this month. The MTD have now been successfully completed, with two species dosed up to the regulatory maximum, 1g/kg of the orexin-1 blocker, with no adverse clinical observations reported. This favourable outcome further de-risks the programme and enables progression into repeat-dose DRF studies, the results of which will inform the dosing for the planned 28-day regulatory toxicity studies scheduled in First Quarter and Second Quarter 2026, depending on species. This is a near final step on the path to IND/CTA readiness targeted for 2026. TheraCryf's lead programme, is a novel, best-in-class orexin-1 blocker., being developed as a potential treatment for addiction, including alcohol and other substance use disorders. The programme demonstrates class-leading selectivity and high receptor occupancy, characteristics which are expected to translate into improved tolerability and efficacy. Blocking the orexin-1 pathway has been shown to reduce aberrant substance-seeking behaviour in animal models, and the orexin pathway has attracted strong interest in the pharmaceutical sector. Addiction represents a large and growing global market, with substantial unmet medical need and significant human, social and economic impact, making it an attractive indication for development and commercialisation.お知らせ • Jan 05Theracryf Plc Starts 2026 Positive, A Key Milestone on the Path to Clinical Ready for Its Ox-1 Orexin Bladder Potential Treatment for Addiction DisordersTheraCryf plc has started 2026 positively, achieving a key milestone on the path to clinical readiness for its Ox-1 orexin blocker potential treatment for addictive disorders. Process for large-scale manufacturing of drug substance established Scale-up achieved on schedule with a manufacturing yield in excess of target 10.6kg produced to supply critical 28-day regulatory toxicology studies. Dosing in two species has now commenced to identify maximum tolerated dose for 28-day regulatory toxicology study. These studies will begin in first quarter of 2026, depending on species. All studies on schedule to complete third quarter of 2026. Manufacturing scale-up and completion of 28-day toxicology studies were highlighted, during the successful placing in March 2025, as the two key milestones remaining in the Ox-1 programme to achieve clinical readiness. Scale-up of the Ox-1 compound to 10kg has now been achieved on schedule and with a yield in excess of expectations. This drug substance will be used in the 28-day regulatory toxicology projects scheduled to commence, in first quarter and second quarter of 2020 in two species. These studies will provide essential data for the planned regulatory submission later in the year and represent the last major hurdle to achieving that goal. Before starting the 28-day toxicology studies, the Maximum Tolerated Dose and Dose Range Finding studies need to be completed. This work has now started. These studies will identify the 'therapeutic index' of the orexin-1 blocker - that is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Ox-1 is TheraCryf's lead asset, an orexin-1 blocker, being developed as a potential treatment for addiction, blocks a pathway in the brain (orexin-1) known to be over-active in individuals with addiction. This group of conditions have significant human and economic impact globally. Blocking the overactivity of this pathway is known to reduce aberrant substance seeking behaviour in animal models. Drugs that can block this pathway have generated significant commercial interest and TheraCryf's orexin-1 blocker is the most selective yet developed, indicating class leading potential.お知らせ • Nov 24Theracryf Plc to Report First Half, 2026 Results on Dec 03, 2025Theracryf Plc announced that they will report first half, 2026 results on Dec 03, 2025お知らせ • Nov 05TheraCryf plc Provides an Update on Key Activity in its Ox-1 Development ProgrammeTheraCryf plc provided an update on key activity in its Ox-1 development programme. 0.5kg scale-up completed, ahead of schedule; Manufacturing of 2kg human grade material initiated; 10kg manufacturing scale-up proceeding to plan. Successful achievement of compound scale-up, from small gram quantities to 0.5kg, is a significant milestone for the Company. This milestone was reached ahead of schedule and with no issues. After formulation to the optimal dosage form, the compound will be used in an in vivo study to identify the 'therapeutic index' this is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Data from this study will inform dosing in the key 28-day toxicology studies scheduled to commence in early 2026. The 28-day toxicology studies will be supplied by the 10kg compound scale-up which is currently proceeding to plan and schedule. The Company have also now initiated work through its partner, Pharmaron, to manufacture drug product for human use in the Ph1 healthy volunteer study. This process is conducted under special conditions, referred to as GMP (Good Manufacturing Practice), a regulatory standard to ensure safety and quality in order that the product can be given to people. Data from this activity will form part of the regulatory package required for the clinical trial application.New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.47m market cap, or US$5.95m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change).お知らせ • Jun 17Theracryf Plc, Annual General Meeting, Jul 09, 2025Theracryf Plc, Annual General Meeting, Jul 09, 2025. Location: the royal society of medicine, 1 wimpole street, w1g 0ae, london United KingdomNew Risk • Jun 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 14% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£5.64m market cap, or US$7.63m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years).お知らせ • May 23Theracryf Plc to Report Fiscal Year 2025 Results on Jun 03, 2025Theracryf Plc announced that they will report fiscal year 2025 results on Jun 03, 2025お知らせ • May 02Theracryf Plc Announces Appointment of Edward Wardle as Non-Executive Director, Effective 1 May 2025Theracryf Plc announced the appointment of Edward Wardle to the Board as a Non-Executive Director, effective 1 May 2025. Edward is nominated by Tracarta Ltd, TheraCryf's largest shareholder. He brings board-level experience in strategy, corporate governance, and business development. Edward has founded and led multiple businesses and is currently an investment advisor with Tracarta Ltd. and Northern Standard Ltd, focusing on critical industries and cutting-edge technologies. He also serves as Senior Business Development Executive at Ironveld PLC.New Risk • Mar 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.79m market cap, or US$6.23m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).New Risk • Feb 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.30m market cap, or US$5.41m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).お知らせ • Feb 19Theracryf Plc has completed a Follow-on Equity Offering in the amount of £4.25 million.Theracryf Plc has completed a Follow-on Equity Offering in the amount of £4.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,288,800,000 Price\Range: £0.0025 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,200,000 Price\Range: £0.0025 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000,000 Price\Range: £0.0025 Transaction Features: Subsequent Direct ListingNew Risk • Jan 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.1m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£3.22m market cap, or US$4.00m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.8m net loss next year).New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£3.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.2m free cash flow). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£2.31m market cap, or US$2.93m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.8m net loss next year).お知らせ • Nov 14Theracryf Plc to Report First Half, 2025 Results on Nov 28, 2024Theracryf Plc announced that they will report first half, 2025 results on Nov 28, 2024Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Alan Barge was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 05Theracryf Plc Announces Demise of Sue Foden, ChairTheraCryf plc announced with deep sadness the sudden passing of Dr. Sue Foden, the Company's Chair. Sue was appointed as a non-executive director to TheraCryf plc (then Evgen Pharma plc) in 2015, becoming Chair in September 2023. Over the past nine years, she has been a valuable advisor and support to the leadership team and Company overall. Her passing is a great loss to the Biotech sector in the UK and beyond. The Company will seek an additional non-executive director as soon as practicable.New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£396k revenue, or US$503k). Market cap is less than US$10m (UK£2.99m market cap, or US$3.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£1.9m net loss in 2 years).お知らせ • Jun 22Theracryf Plc, Annual General Meeting, Jul 18, 2024Theracryf Plc, Annual General Meeting, Jul 18, 2024. Location: the block 11 lecture theatre, alderley park conference centre, nether alderley, cheshire, sk10 4tg, United Kingdomお知らせ • May 21Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024Theracryf Plc announced that they will report fiscal year 2024 results on May 28, 2024New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Market cap is less than US$10m (UK£3.21m market cap, or US$4.07m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (UK£838k revenue, or US$1.1m).お知らせ • Apr 04Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,167,000 Price\Range: £0.01 Transaction Features: Regulation Sお知らせ • Mar 20+ 1 more updateEvgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.01お知らせ • Feb 27Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon CancerEvgen Pharma plc announced that the laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun at the University of Michigan, USA have observed activity of SFX-01 in models of colon cancer. The in vitro and in vivo studies, funded by the USA National Cancer Institute and the University of Michigan will be generating data continuously throughout the project.お知らせ • Feb 20Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm CellsEvgen Pharma plc announced that the laboratory of Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells. The in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a €1.1m project, are designed to investigate the activity of SFX-01 in preclinical GBM models. This work is to be followed by administration of SFX-01 to patients with GBM in a clinical Investigator Sponsored Study (ISS). The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period.お知らせ • Jan 17Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SAEvgen Pharma plc announced a private placement for the gross proceeds of $17,400,000 on January 16, 2024. The transaction included participation from new investor Stalicla SA.New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Market cap is less than US$10m (UK£3.71m market cap, or US$4.69m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Revenue is less than US$5m (UK£838k revenue, or US$1.1m).お知らせ • Dec 22+ 1 more updateEvgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024Evgen Pharma plc announced that Toni Hänninen has been appointed as permanent Chief Financial Officer (CFO). Toni Hänninen was appointed interim CFO in September 2023. He is now taking on the CFO role on a permanent basis. His appointment is effective from 1 January 2024. Toni was previously CFO at Faron Pharmaceuticals Ltd, an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US, developing novel treatments for medical conditions with significant unmet needs. He holds over 20 years of experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. Toni has an MBA from the Helsinki School of Economics (now Aalto University).お知らせ • Oct 27Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma StudiesEvgen Pharma plc and Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Center, announce the formal start of their collaborative project in glioblastoma, supported with a grant awarded by the KWF Dutch Cancer Society. The grant start conditions and documentation have been satisfied and the project formally commenced on 1 October. The studies, which are funded by a grant towards total project costs of approx. EUR 1.1 million awarded by the KWF Dutch cancer Society, will investigate the use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS), aiming to establish the presence of the drug in human brain tumours and engagement with relevant molecular targets in excised tumour tissue. The Erasmus University Medical Center team has also appointed a dedicated, grant funded PhD student, who starts in early November. The project is being carried out in the laboratory and clinic of Dr Marjolein GeURts, neuro-oncologists at Erasmus Medical Center, Cancer Institute, Rotterdam, in the Netherlands and will run for three years, generating data continuously throughout the period. Standard of care for glioblastoma patients is surgery, radiotherapy and chemotherapy, however it is still a disease of significant high unmet need where patient survival rates from diagnosis are between 1 and 3 years and new effective treatment options are sorely needed.お知らせ • Sep 05+ 1 more updateEvgen Pharma plc Announces Executive ChangesEvgen Pharma plc announced the appointment of Toni Hänninen as interim Chief Financial Officer. Evgen Pharma also confirms that Toni Hänninen will take over as interim CFO following Richard Moulson's retirement in July. Toni was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US developing novel treatments for medical conditions with significant unmet needs. He holds over 20 years of experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. Toni has an MBA from the Helsinki School of Economics (currently Aalto University).お知らせ • Aug 17Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation ApprovedEvgen Pharma plc reported the final data from its Phase 1b healthy volunteer study using the Company's new enteric coated tablet formation of lead asset SFX-01. The data are contained in the extensive Clinical Study Report (CSR) which has been approved by the Company and its providers in compliance with good clinical practice (GCP). Highlights · As reported in March 2023, based on the time course seen, sulforaphane was released by the new enteric coated tablet beyond the acid environment of the stomach · No serious adverse events were observed · Total blood levels of sulforaphane (SFN) and SFN-metabolites were confirmed in the micromolar range, where efficacy is seen in vitro · Additional pharmacodynamic exploratory investigation, utilising mRNA sequencing, showed changes in gene expression after dosing with SFX-01 even in healthy volunteers In addition to the biomarkers analysed in the study and contained within the CSR, changes in gene expression were measured by mRNA sequencing on participants' blood, for placebo and SFX-01 treated subjects that received 600mg once daily. The initial analysis identified a large number of significant differentially expressed genes in the SFX-01 treated group, between blood samples taken before the first dose was administered (baseline) and blood samples taken after the first dose timepoint (6 hours after first dose). Further analysis will be undertaken on this large and complex dataset to gain insight into the particular genes identified. Further disease-related mechanistic insight will also be provided from future clinical studies in patients.New Risk • Aug 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.70m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (UK£442k revenue, or US$562k). Market cap is less than US$10m (UK£7.70m market cap, or US$9.78m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.6m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (UK£442k revenue, or US$571k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.6m net loss next year). Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (UK£9.35m market cap, or US$12.1m).お知らせ • Jun 21Evgen Pharma plc, Annual General Meeting, Jul 20, 2023Evgen Pharma plc, Annual General Meeting, Jul 20, 2023, at 13:00 Coordinated Universal Time. Location: the Block 11 Lecture Theatre, Alderley Park, Congleton Road, Nether Alderley, Cheshire, SK10 4TG London United KingdomMajor Estimate Revision • Jun 14Consensus revenue estimates fall by 92%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£4.86m to UK£400.0k. Forecast losses increased from -UK£0.0019 to -UK£0.013 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 0.7% next year. Consensus price target up from UK£0.19 to UK£0.20. Share price fell 6.8% to UK£0.034 over the past week.お知らせ • May 27Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023Evgen Pharma plc announced that they will report Q4, 2023 results on Jun 07, 2023お知らせ • Jan 25Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts DosedEvgen Pharma plc announced that further to its announcement of 16 November 2022, it has completed the dosing of all three cohorts of its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. The study aims toprovide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the Company's lead asset SFX-01, as well asinvestigating how sulforaphane released from SFX-01 engages with molecular targets of interest. Each cohort comprises 8 healthy volunteers dosed with either SFX-01 or placebo. The dosing has been completed on schedule and analysis of the data is ongoing. The trial is on track to report full data in the second quarter of the year as indicated previously. The new enteric-coated tablet formulation will replace the previous prototype capsule formulation. It releases sulforaphane to a targeted part of the intestine, with the goals of predicable release and minimisation of gastro-intestinal side effects. The new formulation, if it performs as expected, will be suitable for large scale trials and commercial supply.Major Estimate Revision • Dec 15Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from UK£450.0k to UK£500.0k. Forecast EPS reduced from -UK£0.01 to -UK£0.01 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target up from UK£0.18 to UK£0.20. Share price fell 15% to UK£0.05 over the past week.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Oct 11Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Nov 24We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Aug 06Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Apr 09Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 25We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...株主還元TCFGB BiotechsGB 市場7D-2.1%1.4%2.5%1Y-6.1%26.9%19.4%株主還元を見る業界別リターン: TCF過去 1 年間で26.9 % の収益を上げたUK Biotechs業界を下回りました。リターン対市場: TCFは、過去 1 年間で19.4 % のリターンを上げたUK市場を下回りました。価格変動Is TCF's price volatile compared to industry and market?TCF volatilityTCF Average Weekly Movement7.4%Biotechs Industry Average Movement9.8%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%安定した株価: TCF 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: TCFの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20149Huw Jonestheracryf.comTheracryf Plcは臨床段階にある治療薬企業で、がんおよび行動脳障害の治療薬の開発に従事している。主力製品はSFX-01で、転移性乳癌の治療薬として第II相臨床試験中、神経発達障害と神経膠芽腫の治療薬として第I相臨床試験中、横紋筋肉腫の治療薬として前臨床段階にある。また、依存症や不安を対象とした前臨床試験後期のオレキシン1拮抗薬、疲労やナルコレプシーを対象とした前臨床試験後期の非定型ドパミントランスポーター阻害薬（DAT）の開発にも取り組んでいる。同社は以前Evgen Pharma plcとして知られていたが、2024年4月にTheracryf Plcに社名を変更した。Theracryf Plcは2014年に法人化され、英国のネザー・アルダーリーに本社を置いている。もっと見るTheracryf Plc 基礎のまとめTheracryf の収益と売上を時価総額と比較するとどうか。TCF 基礎統計学時価総額UK£4.94m収益（TTM）-UK£2.01m売上高(TTM)n/a0.0xP/Sレシオ-2.5xPER（株価収益率TCF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TCF 損益計算書（TTM）収益UK£0売上原価UK£2.23m売上総利益-UK£2.23mその他の費用-UK£224.00k収益-UK£2.01m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.00093グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%TCF の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:00終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Theracryf Plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Colin SmithCapital Access Group
New Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (UK£5.26m market cap, or US$7.06m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change).
お知らせ • Jan 27Theracryf plc Receives Notice of Allowance from the Canadian Patent Office for Its Orexin-1 Addiction ProgrammeTheraCryf plc announced that it has received a Notice of Allowance from the Canadian Patent Office for its Orexin-1 (Ox-1) addiction programme, alongside a positive update on ongoing preclinical development. The Canadian patent represents the final major market to grant for this intellectual property, completing broad protection across the US, Europe, Canada and key Asian territories. The patent provides Composition of Matter, the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme. The Group also reports continued progress on its Maximum Tolerated Dose (MTD) and Dose Range Finding (DRF) studies, which commenced earlier this month. The MTD have now been successfully completed, with two species dosed up to the regulatory maximum, 1g/kg of the orexin-1 blocker, with no adverse clinical observations reported. This favourable outcome further de-risks the programme and enables progression into repeat-dose DRF studies, the results of which will inform the dosing for the planned 28-day regulatory toxicity studies scheduled in First Quarter and Second Quarter 2026, depending on species. This is a near final step on the path to IND/CTA readiness targeted for 2026. TheraCryf's lead programme, is a novel, best-in-class orexin-1 blocker., being developed as a potential treatment for addiction, including alcohol and other substance use disorders. The programme demonstrates class-leading selectivity and high receptor occupancy, characteristics which are expected to translate into improved tolerability and efficacy. Blocking the orexin-1 pathway has been shown to reduce aberrant substance-seeking behaviour in animal models, and the orexin pathway has attracted strong interest in the pharmaceutical sector. Addiction represents a large and growing global market, with substantial unmet medical need and significant human, social and economic impact, making it an attractive indication for development and commercialisation.
お知らせ • Jan 05Theracryf Plc Starts 2026 Positive, A Key Milestone on the Path to Clinical Ready for Its Ox-1 Orexin Bladder Potential Treatment for Addiction DisordersTheraCryf plc has started 2026 positively, achieving a key milestone on the path to clinical readiness for its Ox-1 orexin blocker potential treatment for addictive disorders. Process for large-scale manufacturing of drug substance established Scale-up achieved on schedule with a manufacturing yield in excess of target 10.6kg produced to supply critical 28-day regulatory toxicology studies. Dosing in two species has now commenced to identify maximum tolerated dose for 28-day regulatory toxicology study. These studies will begin in first quarter of 2026, depending on species. All studies on schedule to complete third quarter of 2026. Manufacturing scale-up and completion of 28-day toxicology studies were highlighted, during the successful placing in March 2025, as the two key milestones remaining in the Ox-1 programme to achieve clinical readiness. Scale-up of the Ox-1 compound to 10kg has now been achieved on schedule and with a yield in excess of expectations. This drug substance will be used in the 28-day regulatory toxicology projects scheduled to commence, in first quarter and second quarter of 2020 in two species. These studies will provide essential data for the planned regulatory submission later in the year and represent the last major hurdle to achieving that goal. Before starting the 28-day toxicology studies, the Maximum Tolerated Dose and Dose Range Finding studies need to be completed. This work has now started. These studies will identify the 'therapeutic index' of the orexin-1 blocker - that is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Ox-1 is TheraCryf's lead asset, an orexin-1 blocker, being developed as a potential treatment for addiction, blocks a pathway in the brain (orexin-1) known to be over-active in individuals with addiction. This group of conditions have significant human and economic impact globally. Blocking the overactivity of this pathway is known to reduce aberrant substance seeking behaviour in animal models. Drugs that can block this pathway have generated significant commercial interest and TheraCryf's orexin-1 blocker is the most selective yet developed, indicating class leading potential.
お知らせ • Nov 24Theracryf Plc to Report First Half, 2026 Results on Dec 03, 2025Theracryf Plc announced that they will report first half, 2026 results on Dec 03, 2025
お知らせ • Nov 05TheraCryf plc Provides an Update on Key Activity in its Ox-1 Development ProgrammeTheraCryf plc provided an update on key activity in its Ox-1 development programme. 0.5kg scale-up completed, ahead of schedule; Manufacturing of 2kg human grade material initiated; 10kg manufacturing scale-up proceeding to plan. Successful achievement of compound scale-up, from small gram quantities to 0.5kg, is a significant milestone for the Company. This milestone was reached ahead of schedule and with no issues. After formulation to the optimal dosage form, the compound will be used in an in vivo study to identify the 'therapeutic index' this is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Data from this study will inform dosing in the key 28-day toxicology studies scheduled to commence in early 2026. The 28-day toxicology studies will be supplied by the 10kg compound scale-up which is currently proceeding to plan and schedule. The Company have also now initiated work through its partner, Pharmaron, to manufacture drug product for human use in the Ph1 healthy volunteer study. This process is conducted under special conditions, referred to as GMP (Good Manufacturing Practice), a regulatory standard to ensure safety and quality in order that the product can be given to people. Data from this activity will form part of the regulatory package required for the clinical trial application.
New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.47m market cap, or US$5.95m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change).
New Risk • May 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (UK£5.26m market cap, or US$7.06m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.5m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change).
お知らせ • Jan 27Theracryf plc Receives Notice of Allowance from the Canadian Patent Office for Its Orexin-1 Addiction ProgrammeTheraCryf plc announced that it has received a Notice of Allowance from the Canadian Patent Office for its Orexin-1 (Ox-1) addiction programme, alongside a positive update on ongoing preclinical development. The Canadian patent represents the final major market to grant for this intellectual property, completing broad protection across the US, Europe, Canada and key Asian territories. The patent provides Composition of Matter, the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme. The Group also reports continued progress on its Maximum Tolerated Dose (MTD) and Dose Range Finding (DRF) studies, which commenced earlier this month. The MTD have now been successfully completed, with two species dosed up to the regulatory maximum, 1g/kg of the orexin-1 blocker, with no adverse clinical observations reported. This favourable outcome further de-risks the programme and enables progression into repeat-dose DRF studies, the results of which will inform the dosing for the planned 28-day regulatory toxicity studies scheduled in First Quarter and Second Quarter 2026, depending on species. This is a near final step on the path to IND/CTA readiness targeted for 2026. TheraCryf's lead programme, is a novel, best-in-class orexin-1 blocker., being developed as a potential treatment for addiction, including alcohol and other substance use disorders. The programme demonstrates class-leading selectivity and high receptor occupancy, characteristics which are expected to translate into improved tolerability and efficacy. Blocking the orexin-1 pathway has been shown to reduce aberrant substance-seeking behaviour in animal models, and the orexin pathway has attracted strong interest in the pharmaceutical sector. Addiction represents a large and growing global market, with substantial unmet medical need and significant human, social and economic impact, making it an attractive indication for development and commercialisation.
お知らせ • Jan 05Theracryf Plc Starts 2026 Positive, A Key Milestone on the Path to Clinical Ready for Its Ox-1 Orexin Bladder Potential Treatment for Addiction DisordersTheraCryf plc has started 2026 positively, achieving a key milestone on the path to clinical readiness for its Ox-1 orexin blocker potential treatment for addictive disorders. Process for large-scale manufacturing of drug substance established Scale-up achieved on schedule with a manufacturing yield in excess of target 10.6kg produced to supply critical 28-day regulatory toxicology studies. Dosing in two species has now commenced to identify maximum tolerated dose for 28-day regulatory toxicology study. These studies will begin in first quarter of 2026, depending on species. All studies on schedule to complete third quarter of 2026. Manufacturing scale-up and completion of 28-day toxicology studies were highlighted, during the successful placing in March 2025, as the two key milestones remaining in the Ox-1 programme to achieve clinical readiness. Scale-up of the Ox-1 compound to 10kg has now been achieved on schedule and with a yield in excess of expectations. This drug substance will be used in the 28-day regulatory toxicology projects scheduled to commence, in first quarter and second quarter of 2020 in two species. These studies will provide essential data for the planned regulatory submission later in the year and represent the last major hurdle to achieving that goal. Before starting the 28-day toxicology studies, the Maximum Tolerated Dose and Dose Range Finding studies need to be completed. This work has now started. These studies will identify the 'therapeutic index' of the orexin-1 blocker - that is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Ox-1 is TheraCryf's lead asset, an orexin-1 blocker, being developed as a potential treatment for addiction, blocks a pathway in the brain (orexin-1) known to be over-active in individuals with addiction. This group of conditions have significant human and economic impact globally. Blocking the overactivity of this pathway is known to reduce aberrant substance seeking behaviour in animal models. Drugs that can block this pathway have generated significant commercial interest and TheraCryf's orexin-1 blocker is the most selective yet developed, indicating class leading potential.
お知らせ • Nov 24Theracryf Plc to Report First Half, 2026 Results on Dec 03, 2025Theracryf Plc announced that they will report first half, 2026 results on Dec 03, 2025
お知らせ • Nov 05TheraCryf plc Provides an Update on Key Activity in its Ox-1 Development ProgrammeTheraCryf plc provided an update on key activity in its Ox-1 development programme. 0.5kg scale-up completed, ahead of schedule; Manufacturing of 2kg human grade material initiated; 10kg manufacturing scale-up proceeding to plan. Successful achievement of compound scale-up, from small gram quantities to 0.5kg, is a significant milestone for the Company. This milestone was reached ahead of schedule and with no issues. After formulation to the optimal dosage form, the compound will be used in an in vivo study to identify the 'therapeutic index' this is the range between which the dose is expected to have a therapeutic effect and the highest dose of compound reached before any harmful effects are observed. Data from this study will inform dosing in the key 28-day toxicology studies scheduled to commence in early 2026. The 28-day toxicology studies will be supplied by the 10kg compound scale-up which is currently proceeding to plan and schedule. The Company have also now initiated work through its partner, Pharmaron, to manufacture drug product for human use in the Ph1 healthy volunteer study. This process is conducted under special conditions, referred to as GMP (Good Manufacturing Practice), a regulatory standard to ensure safety and quality in order that the product can be given to people. Data from this activity will form part of the regulatory package required for the clinical trial application.
New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.47m market cap, or US$5.95m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years). Share price has been volatile over the past 3 months (7.1% average weekly change).
お知らせ • Jun 17Theracryf Plc, Annual General Meeting, Jul 09, 2025Theracryf Plc, Annual General Meeting, Jul 09, 2025. Location: the royal society of medicine, 1 wimpole street, w1g 0ae, london United Kingdom
New Risk • Jun 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 14% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (398% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£5.64m market cap, or US$7.63m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.6m net loss in 2 years).
お知らせ • May 23Theracryf Plc to Report Fiscal Year 2025 Results on Jun 03, 2025Theracryf Plc announced that they will report fiscal year 2025 results on Jun 03, 2025
お知らせ • May 02Theracryf Plc Announces Appointment of Edward Wardle as Non-Executive Director, Effective 1 May 2025Theracryf Plc announced the appointment of Edward Wardle to the Board as a Non-Executive Director, effective 1 May 2025. Edward is nominated by Tracarta Ltd, TheraCryf's largest shareholder. He brings board-level experience in strategy, corporate governance, and business development. Edward has founded and led multiple businesses and is currently an investment advisor with Tracarta Ltd. and Northern Standard Ltd, focusing on critical industries and cutting-edge technologies. He also serves as Senior Business Development Executive at Ironveld PLC.
New Risk • Mar 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.79m market cap, or US$6.23m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).
New Risk • Feb 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.30m market cap, or US$5.41m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).
お知らせ • Feb 19Theracryf Plc has completed a Follow-on Equity Offering in the amount of £4.25 million.Theracryf Plc has completed a Follow-on Equity Offering in the amount of £4.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,288,800,000 Price\Range: £0.0025 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,200,000 Price\Range: £0.0025 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000,000 Price\Range: £0.0025 Transaction Features: Subsequent Direct Listing
New Risk • Jan 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.1m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£3.22m market cap, or US$4.00m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.8m net loss next year).
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£3.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.2m free cash flow). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£2.31m market cap, or US$2.93m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.8m net loss next year).
お知らせ • Nov 14Theracryf Plc to Report First Half, 2025 Results on Nov 28, 2024Theracryf Plc announced that they will report first half, 2025 results on Nov 28, 2024
Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Alan Barge was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 05Theracryf Plc Announces Demise of Sue Foden, ChairTheraCryf plc announced with deep sadness the sudden passing of Dr. Sue Foden, the Company's Chair. Sue was appointed as a non-executive director to TheraCryf plc (then Evgen Pharma plc) in 2015, becoming Chair in September 2023. Over the past nine years, she has been a valuable advisor and support to the leadership team and Company overall. Her passing is a great loss to the Biotech sector in the UK and beyond. The Company will seek an additional non-executive director as soon as practicable.
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£396k revenue, or US$503k). Market cap is less than US$10m (UK£2.99m market cap, or US$3.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£1.9m net loss in 2 years).
お知らせ • Jun 22Theracryf Plc, Annual General Meeting, Jul 18, 2024Theracryf Plc, Annual General Meeting, Jul 18, 2024. Location: the block 11 lecture theatre, alderley park conference centre, nether alderley, cheshire, sk10 4tg, United Kingdom
お知らせ • May 21Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024Theracryf Plc announced that they will report fiscal year 2024 results on May 28, 2024
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Market cap is less than US$10m (UK£3.21m market cap, or US$4.07m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (UK£838k revenue, or US$1.1m).
お知らせ • Apr 04Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,167,000 Price\Range: £0.01 Transaction Features: Regulation S
お知らせ • Mar 20+ 1 more updateEvgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.01
お知らせ • Feb 27Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon CancerEvgen Pharma plc announced that the laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun at the University of Michigan, USA have observed activity of SFX-01 in models of colon cancer. The in vitro and in vivo studies, funded by the USA National Cancer Institute and the University of Michigan will be generating data continuously throughout the project.
お知らせ • Feb 20Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm CellsEvgen Pharma plc announced that the laboratory of Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells. The in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a €1.1m project, are designed to investigate the activity of SFX-01 in preclinical GBM models. This work is to be followed by administration of SFX-01 to patients with GBM in a clinical Investigator Sponsored Study (ISS). The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period.
お知らせ • Jan 17Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SAEvgen Pharma plc announced a private placement for the gross proceeds of $17,400,000 on January 16, 2024. The transaction included participation from new investor Stalicla SA.
New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Market cap is less than US$10m (UK£3.71m market cap, or US$4.69m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Revenue is less than US$5m (UK£838k revenue, or US$1.1m).
お知らせ • Dec 22+ 1 more updateEvgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024Evgen Pharma plc announced that Toni Hänninen has been appointed as permanent Chief Financial Officer (CFO). Toni Hänninen was appointed interim CFO in September 2023. He is now taking on the CFO role on a permanent basis. His appointment is effective from 1 January 2024. Toni was previously CFO at Faron Pharmaceuticals Ltd, an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US, developing novel treatments for medical conditions with significant unmet needs. He holds over 20 years of experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. Toni has an MBA from the Helsinki School of Economics (now Aalto University).
お知らせ • Oct 27Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma StudiesEvgen Pharma plc and Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Center, announce the formal start of their collaborative project in glioblastoma, supported with a grant awarded by the KWF Dutch Cancer Society. The grant start conditions and documentation have been satisfied and the project formally commenced on 1 October. The studies, which are funded by a grant towards total project costs of approx. EUR 1.1 million awarded by the KWF Dutch cancer Society, will investigate the use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS), aiming to establish the presence of the drug in human brain tumours and engagement with relevant molecular targets in excised tumour tissue. The Erasmus University Medical Center team has also appointed a dedicated, grant funded PhD student, who starts in early November. The project is being carried out in the laboratory and clinic of Dr Marjolein GeURts, neuro-oncologists at Erasmus Medical Center, Cancer Institute, Rotterdam, in the Netherlands and will run for three years, generating data continuously throughout the period. Standard of care for glioblastoma patients is surgery, radiotherapy and chemotherapy, however it is still a disease of significant high unmet need where patient survival rates from diagnosis are between 1 and 3 years and new effective treatment options are sorely needed.
お知らせ • Sep 05+ 1 more updateEvgen Pharma plc Announces Executive ChangesEvgen Pharma plc announced the appointment of Toni Hänninen as interim Chief Financial Officer. Evgen Pharma also confirms that Toni Hänninen will take over as interim CFO following Richard Moulson's retirement in July. Toni was previously CFO at Faron Pharmaceuticals Ltd., an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US developing novel treatments for medical conditions with significant unmet needs. He holds over 20 years of experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector. Toni has an MBA from the Helsinki School of Economics (currently Aalto University).
お知らせ • Aug 17Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation ApprovedEvgen Pharma plc reported the final data from its Phase 1b healthy volunteer study using the Company's new enteric coated tablet formation of lead asset SFX-01. The data are contained in the extensive Clinical Study Report (CSR) which has been approved by the Company and its providers in compliance with good clinical practice (GCP). Highlights · As reported in March 2023, based on the time course seen, sulforaphane was released by the new enteric coated tablet beyond the acid environment of the stomach · No serious adverse events were observed · Total blood levels of sulforaphane (SFN) and SFN-metabolites were confirmed in the micromolar range, where efficacy is seen in vitro · Additional pharmacodynamic exploratory investigation, utilising mRNA sequencing, showed changes in gene expression after dosing with SFX-01 even in healthy volunteers In addition to the biomarkers analysed in the study and contained within the CSR, changes in gene expression were measured by mRNA sequencing on participants' blood, for placebo and SFX-01 treated subjects that received 600mg once daily. The initial analysis identified a large number of significant differentially expressed genes in the SFX-01 treated group, between blood samples taken before the first dose was administered (baseline) and blood samples taken after the first dose timepoint (6 hours after first dose). Further analysis will be undertaken on this large and complex dataset to gain insight into the particular genes identified. Further disease-related mechanistic insight will also be provided from future clinical studies in patients.
New Risk • Aug 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.70m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (UK£442k revenue, or US$562k). Market cap is less than US$10m (UK£7.70m market cap, or US$9.78m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.6m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change).
New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.9% per year over the past 5 years. Revenue is less than US$1m (UK£442k revenue, or US$571k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.6m net loss next year). Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (UK£9.35m market cap, or US$12.1m).
お知らせ • Jun 21Evgen Pharma plc, Annual General Meeting, Jul 20, 2023Evgen Pharma plc, Annual General Meeting, Jul 20, 2023, at 13:00 Coordinated Universal Time. Location: the Block 11 Lecture Theatre, Alderley Park, Congleton Road, Nether Alderley, Cheshire, SK10 4TG London United Kingdom
Major Estimate Revision • Jun 14Consensus revenue estimates fall by 92%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£4.86m to UK£400.0k. Forecast losses increased from -UK£0.0019 to -UK£0.013 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 0.7% next year. Consensus price target up from UK£0.19 to UK£0.20. Share price fell 6.8% to UK£0.034 over the past week.
お知らせ • May 27Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023Evgen Pharma plc announced that they will report Q4, 2023 results on Jun 07, 2023
お知らせ • Jan 25Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts DosedEvgen Pharma plc announced that further to its announcement of 16 November 2022, it has completed the dosing of all three cohorts of its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. The study aims toprovide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the Company's lead asset SFX-01, as well asinvestigating how sulforaphane released from SFX-01 engages with molecular targets of interest. Each cohort comprises 8 healthy volunteers dosed with either SFX-01 or placebo. The dosing has been completed on schedule and analysis of the data is ongoing. The trial is on track to report full data in the second quarter of the year as indicated previously. The new enteric-coated tablet formulation will replace the previous prototype capsule formulation. It releases sulforaphane to a targeted part of the intestine, with the goals of predicable release and minimisation of gastro-intestinal side effects. The new formulation, if it performs as expected, will be suitable for large scale trials and commercial supply.
Major Estimate Revision • Dec 15Consensus forecasts updatedThe consensus outlook for 2023 has been updated. 2023 revenue forecast increased from UK£450.0k to UK£500.0k. Forecast EPS reduced from -UK£0.01 to -UK£0.01 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target up from UK£0.18 to UK£0.20. Share price fell 15% to UK£0.05 over the past week.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Oct 11Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Non-Executive Director Susan Clement-Davies was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Nov 24We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Aug 06Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Apr 09Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Dec 25We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
